$CELG Company News Is the next Cisco out there
Post# of 74540
Posted On: 12/07/2014 12:51:14 PM
$CELG Company News
Is the next Cisco out there? 3:24 p.m. Nov. 25, 2014 - The Trading Deck
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 12:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 1:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 12:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 6:27 a.m. July 9, 2014 - Ciara Linnane
Agios, Celgene to Start Approval Studies of Cancer Metabolism Drug in 2015 20 min ago - TheStreet.com
Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions 1:00 p.m. Dec. 6, 2014 - TheStreet.com
Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting 11:00 a.m. Dec. 6, 2014 - TheStreet.com
Jim Cramer Picks 19 Companies That Should Get Acquired in 2015 9:15 a.m. Dec. 6, 2014 - TheStreet.com
Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences 12:18 p.m. Dec. 5, 2014 - TheStreet.com
'Mad Money' Lightning Round: Buy, Buy, Buy Texas Instruments 6:00 a.m. Dec. 5, 2014 - TheStreet.com
Cramer's Lightning Round - Constellation Brands Has Real Magic (12/4/14) 4:36 a.m. Dec. 5, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks 8:31 p.m. Dec. 4, 2014 - TheStreet.com
Jim Cramer Picks 19 Companies That Should Get Acquired in 2015 2:00 p.m. Dec. 4, 2014 - TheStreet.com
Acetylon Begins Phase 2 Study Of Ricolinostat With Pomalyst 8:08 a.m. Dec. 4, 2014 - benzinga.com
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14) 6:04 a.m. Dec. 4, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now 8:36 p.m. Dec. 3, 2014 - TheStreet.com
'Mad Money' Lightning Round: You're on Your Own With Tesla 6:00 a.m. Dec. 3, 2014 - TheStreet.com
Jim Cramer's Top Stock Picks: REGN BMRN ISIS EOG BIIB CELG DECK ZOES 6:00 a.m. Dec. 3, 2014 - TheStreet.com
Cramer's Lightning Round - Power To The PPL (12/2/14) 5:46 a.m. Dec. 3, 2014 - Seeking Alpha
Cramer's Mad Money - Deckers Is About More Than Just Uggs (12/2/14) 5:33 a.m. Dec. 3, 2014 - Seeking Alpha
‘Fast Money’ Recap: Can Stocks Still Rally if Oil Prices Rebound? 5:00 a.m. Dec. 3, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners 8:21 p.m. Dec. 2, 2014 - TheStreet.com
Top Funds Gobble Up Tech And Medical Stocks 5:19 p.m. Dec. 2, 2014 - Investors Business Daily
Meet 5 Top Drug Stocks That Are Bolting Past Market 7:02 a.m. Dec. 2, 2014 - Investors Business Daily
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Nov. 20, 2014 - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene 9:10 a.m. Oct. 15, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis 8:38 a.m. Oct. 10, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis 8:37 a.m. Oct. 10, 2014 - BusinessWire - BZX
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver 9:31 a.m. Oct. 8, 2014 - PR Newswire - PRF
Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress 7:30 a.m. Oct. 7, 2014 - BusinessWire - BZX
Is the next Cisco out there? 3:24 p.m. Nov. 25, 2014 - The Trading Deck
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 12:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 1:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 12:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 6:27 a.m. July 9, 2014 - Ciara Linnane
Agios, Celgene to Start Approval Studies of Cancer Metabolism Drug in 2015 20 min ago - TheStreet.com
Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions 1:00 p.m. Dec. 6, 2014 - TheStreet.com
Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting 11:00 a.m. Dec. 6, 2014 - TheStreet.com
Jim Cramer Picks 19 Companies That Should Get Acquired in 2015 9:15 a.m. Dec. 6, 2014 - TheStreet.com
Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences 12:18 p.m. Dec. 5, 2014 - TheStreet.com
'Mad Money' Lightning Round: Buy, Buy, Buy Texas Instruments 6:00 a.m. Dec. 5, 2014 - TheStreet.com
Cramer's Lightning Round - Constellation Brands Has Real Magic (12/4/14) 4:36 a.m. Dec. 5, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks 8:31 p.m. Dec. 4, 2014 - TheStreet.com
Jim Cramer Picks 19 Companies That Should Get Acquired in 2015 2:00 p.m. Dec. 4, 2014 - TheStreet.com
Acetylon Begins Phase 2 Study Of Ricolinostat With Pomalyst 8:08 a.m. Dec. 4, 2014 - benzinga.com
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14) 6:04 a.m. Dec. 4, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now 8:36 p.m. Dec. 3, 2014 - TheStreet.com
'Mad Money' Lightning Round: You're on Your Own With Tesla 6:00 a.m. Dec. 3, 2014 - TheStreet.com
Jim Cramer's Top Stock Picks: REGN BMRN ISIS EOG BIIB CELG DECK ZOES 6:00 a.m. Dec. 3, 2014 - TheStreet.com
Cramer's Lightning Round - Power To The PPL (12/2/14) 5:46 a.m. Dec. 3, 2014 - Seeking Alpha
Cramer's Mad Money - Deckers Is About More Than Just Uggs (12/2/14) 5:33 a.m. Dec. 3, 2014 - Seeking Alpha
‘Fast Money’ Recap: Can Stocks Still Rally if Oil Prices Rebound? 5:00 a.m. Dec. 3, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners 8:21 p.m. Dec. 2, 2014 - TheStreet.com
Top Funds Gobble Up Tech And Medical Stocks 5:19 p.m. Dec. 2, 2014 - Investors Business Daily
Meet 5 Top Drug Stocks That Are Bolting Past Market 7:02 a.m. Dec. 2, 2014 - Investors Business Daily
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Nov. 20, 2014 - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene 9:10 a.m. Oct. 15, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis 8:38 a.m. Oct. 10, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis 8:37 a.m. Oct. 10, 2014 - BusinessWire - BZX
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver 9:31 a.m. Oct. 8, 2014 - PR Newswire - PRF
Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress 7:30 a.m. Oct. 7, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼